About
Reversible thrombolytic therapy for acute ischemic stroke
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyMidwest
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
274
By Phase
PHASE1: 2PHASE2: 1
By Status
NOT_YET_RECRUITING: 1RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07202663Lead Sponsor
Study of BB-025, Alone and After BB-031, in Healthy Volunteers
PHASE1Not yet recruiting
72 participants
Started: Dec 31, 2025 · Completed: Jun 30, 2026
NCT06226805Lead Sponsor
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
PHASE2Recruiting
156 participants
Started: Jul 31, 2024 · Completed: Sep 30, 2027
NCT05005520Lead Sponsor
Study of DTRI-031 in Healthy Volunteers
PHASE1Completed
46 participants
Started: Oct 20, 2021 · Completed: Apr 19, 2022
Locations (1)
Headquarters
Columbus, OH, United States
Map
Loading map...